July 28, 2025

Trump Administration Proposes Rule to Lower Medicare Drug Rates

News Summary

The Trump administration’s proposed rule could lower Medicare rates for drugs at hospital-operated clinics, resulting in a projected $40 million loss for New York hospitals. Advocates express concern over financial strains as hospitals face challenges in treating high-acuity patients. The rule seeks to align drug pricing with physician practices, altering previous policies that allowed higher charges. Further state legislation is also being discussed to implement site-neutral payments, potentially saving New Yorkers $1 billion annually. The implications of these changes could reshape the healthcare funding landscape in New York.

New York City – The Trump Administration has proposed a rule that aims to lower Medicare rates for drugs administered at hospital-operated clinics, potentially leading to significant financial strains on healthcare providers in New York. If enacted, this new regulation is projected to result in a $40 million loss for hospitals across the state in the upcoming year.

The proposed rule seeks to align the drug pricing at off-site clinics operated by hospitals with the rates charged by traditional physician practices for the same medications. This change comes from the Centers for Medicare and Medicaid Services (CMS) and marks a notable shift from an Obama-era policy that allowed hospitals to charge higher prices for drugs used in treatments at offsite facilities such as chemotherapy clinics.

The Greater New York Hospital Association (GNYHA), which represents the interests of New York’s health systems, expressed strong concerns regarding the proposal in a letter sent to hospital CEOs. As a significant advocate for the state’s hospitals, GNYHA emphasized that the higher fees hospitals currently receive are crucial for covering their overhead costs. They argue that off-site clinics typically cater to a higher acuity of patients, which necessitates additional resources and financing.

According to CMS’s estimates, the implementation of this new rule could lead to total savings of around $280 million, which includes $210 million in lower Medicare spending and an additional $70 million affecting patient expenses. However, these financial benefits come at the potential cost to hospitals within the state, which have already faced ongoing financial challenges.

The repercussions of such cuts echo previous attempts by GNYHA to prevent reductions in Medicaid funding as part of a reconciliation package signed by President Trump earlier this year. Healthcare administrators are concerned that the proposed cuts would further exacerbate the financial difficulties many hospitals already face.

Healthcare leaders argue that the ability to charge higher rates for drugs is necessary for their operational stability. They point to the complexities and demands of treating sicker patients and maintaining the facilities necessary for outpatient services. Furthermore, there is an ongoing concern that current pricing incentivizes hospitals to invest in outpatient facilities excessively, rather than focusing on the critical clinical needs of their patient population.

Alongside this federal proposal, state-level legislation in Albany is being considered that would implement site-neutral payments. This legislation could save New Yorkers approximately $1 billion annually, highlighting the interconnectedness of healthcare funding discussions at both state and federal levels. Additionally, CMS is inviting public feedback on the possibility of expanding site-neutral payment policies to include on-campus clinics, further stirring debate among hospital administrators and policymakers.

The potential financial implications for New York hospitals have been underscored by GNYHA President Kenneth Raske’s assertion that further cuts could lead to serious consequences for healthcare providers unable to absorb any additional losses.

This proposed rule by the Trump administration represents part of a broader strategy intended to manage spiraling healthcare costs, a concern that has drawn criticism from various stakeholders within the industry. As discussions continue, the healthcare landscape in New York could experience notable changes depending on the outcomes of both federal and state-level initiatives aimed at reshaping drug pricing and healthcare funding mechanisms.